Citi reiterates a 'Buy' rating on Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). Price target $52.

Citi analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE